181 related articles for article (PubMed ID: 21849509)
1. Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.
Lusher SJ; Raaijmakers HC; Vu-Pham D; Dechering K; Lam TW; Brown AR; Hamilton NM; Nimz O; Bosch R; McGuire R; Oubrie A; de Vlieg J
J Biol Chem; 2011 Oct; 286(40):35079-86. PubMed ID: 21849509
[TBL] [Abstract][Full Text] [Related]
2. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation.
Raaijmakers HC; Versteegh JE; Uitdehaag JC
J Biol Chem; 2009 Jul; 284(29):19572-9. PubMed ID: 19372222
[TBL] [Abstract][Full Text] [Related]
3. X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.
Lusher SJ; Raaijmakers HC; Vu-Pham D; Kazemier B; Bosch R; McGuire R; Azevedo R; Hamersma H; Dechering K; Oubrie A; van Duin M; de Vlieg J
J Biol Chem; 2012 Jun; 287(24):20333-43. PubMed ID: 22535964
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor.
Vegeto E; Allan GF; Schrader WT; Tsai MJ; McDonnell DP; O'Malley BW
Cell; 1992 May; 69(4):703-13. PubMed ID: 1586949
[TBL] [Abstract][Full Text] [Related]
5. Comparison between steroid binding to membrane progesterone receptor alpha (mPRalpha) and to nuclear progesterone receptor: correlation with physicochemical properties assessed by comparative molecular field analysis and identification of mPRalpha-specific agonists.
Kelder J; Azevedo R; Pang Y; de Vlieg J; Dong J; Thomas P
Steroids; 2010 Apr; 75(4-5):314-22. PubMed ID: 20096719
[TBL] [Abstract][Full Text] [Related]
6. Atomic structure of progesterone complexed with its receptor.
Williams SP; Sigler PB
Nature; 1998 May; 393(6683):392-6. PubMed ID: 9620806
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor and the mechanism of action of progesterone antagonists.
Edwards DP; Altmann M; DeMarzo A; Zhang Y; Weigel NL; Beck CA
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):449-58. PubMed ID: 7626494
[TBL] [Abstract][Full Text] [Related]
8. X-ray crystal structure of the ancestral 3-ketosteroid receptor-progesterone-mifepristone complex shows mifepristone bound at the coactivator binding interface.
Colucci JK; Ortlund EA
PLoS One; 2013; 8(11):e80761. PubMed ID: 24260475
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes.
Madauss KP; Deng SJ; Austin RJ; Lambert MH; McLay I; Pritchard J; Short SA; Stewart EL; Uings IJ; Williams SP
J Med Chem; 2004 Jun; 47(13):3381-7. PubMed ID: 15189034
[TBL] [Abstract][Full Text] [Related]
10. 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity.
Wagner BL; Pollio G; Leonhardt S; Wani MC; Lee DY; Imhof MO; Edwards DP; Cook CE; McDonnell DP
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8739-44. PubMed ID: 8710941
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.
Afhüppe W; Beekman JM; Otto C; Korr D; Hoffmann J; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):45-55. PubMed ID: 20043998
[TBL] [Abstract][Full Text] [Related]
12. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity.
Elger W; Bartley J; Schneider B; Kaufmann G; Schubert G; Chwalisz K
Steroids; 2000; 65(10-11):713-23. PubMed ID: 11108882
[TBL] [Abstract][Full Text] [Related]
13. Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.
Thompson SK; Washburn DG; Frazee JS; Madauss KP; Hoang TH; Lapinski L; Grygielko ET; Glace LE; Trizna W; Williams SP; Duraiswami C; Bray JD; Laping NJ
Bioorg Med Chem Lett; 2009 Aug; 19(16):4777-80. PubMed ID: 19595590
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel mechanism of steroid receptor antagonism: WAY-255348 modulates progesterone receptor cellular localization and promoter interactions.
Yudt MR; Russo LA; Berrodin TJ; Jelinsky SA; Ellis D; Cohen JC; Cooch N; Haglund E; Unwalla RJ; Fensome A; Wrobel J; Zhang Z; Nagpal S; Winneker RC
Biochem Pharmacol; 2011 Dec; 82(11):1709-19. PubMed ID: 21854761
[TBL] [Abstract][Full Text] [Related]
15. Agonistic and Antagonistic Effects of Progesterone Derivatives on the Transcriptional Activity of Nuclear Progesterone Receptor B in Yeast Model System.
Michurina AO; Polikarpova AV; Levina IS; Kulikova LE; Zavarzin IV; Guseva AA; Morozov IA; Rubtsov PM; Smirnova OV; Shchelkunova TA
Biochemistry (Mosc); 2018 May; 83(5):574-585. PubMed ID: 29738691
[TBL] [Abstract][Full Text] [Related]
16. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.
Lebon G; Warne T; Edwards PC; Bennett K; Langmead CJ; Leslie AG; Tate CG
Nature; 2011 May; 474(7352):521-5. PubMed ID: 21593763
[TBL] [Abstract][Full Text] [Related]
17. Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay.
Leonhardt SA; Altmann M; Edwards DP
Mol Endocrinol; 1998 Dec; 12(12):1914-30. PubMed ID: 9849965
[TBL] [Abstract][Full Text] [Related]
18. 6-arylcoumarins as novel nonsteroidal type progesterone antagonists: an example with receptor-binding-dependent fluorescence.
Sakai H; Hirano T; Mori S; Fujii S; Masuno H; Kinoshita M; Kagechika H; Tanatani A
J Med Chem; 2011 Oct; 54(20):7055-65. PubMed ID: 21916484
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors.
Petit-Topin I; Fay M; Resche-Rigon M; Ulmann A; Gainer E; Rafestin-Oblin ME; Fagart J
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():427-35. PubMed ID: 25204619
[TBL] [Abstract][Full Text] [Related]
20. Switching agonistic, antagonistic, and mixed transcriptional responses to 11 beta-substituted progestins by mutation of the progesterone receptor.
Garcia T; Benhamou B; Gofflo D; Vergezac A; Philibert D; Chambon P; Gronemeyer H
Mol Endocrinol; 1992 Dec; 6(12):2071-8. PubMed ID: 1337143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
